SUBSCRIBE
SUBSCRIBE
News   Policy

Antares Pharma, Inc. Announces Filing of New Drug Application for Anturol for Overactive Bladder

December 22, 2010 | 
1 min read
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Anturol® Gel in patients with overactive bladder (OAB).
Regulatory
MORE ON THIS TOPIC
Human brain with abstract visualization of neuron activity
Huntington’s disease
FDA Official Fires Back at UniQure, Doubles Down on Sham-Controlled Trial
March 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
FDA
FDA’s Hoeg Reportedly Trying To Hire Friend, Fellow Antidepressant Skeptic
March 5, 2026
 · 
2 min read
 · 
Tristan Manalac
Business decision concept with a businessman standing on a huge question mark. Symbol of the future, opportunities, planning, vision. Vector illustration
Regulatory
PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause
March 5, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of a yellow envelope on a blue background with a read warning symbol
Supply chain
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s
March 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor